

Referral Status:		MRN:	
<input type="checkbox"/> New referral	<input type="checkbox"/> Order change	<input type="checkbox"/> Order Renewal	
Patient preferred clinic:			

Xolair® (omalizumab) Standard Plan of Treatment for Nasal Polyps

Rev. 4.30.25

PATIENT DEMOGRAPHICS:

Patient Name:			
Patient's Phone:		Address:	
Date of Birth:		City, State, Zip:	
Height in inches:	Weight:	LB or KG Gender:	Allergies: <input type="checkbox"/> See list <input type="checkbox"/> NKDA

DIAGNOSIS: (PLEASE COMPLETE 2ND AND 3RD DIGITS TO COMPLETE ICD 10 FOR BILLING)

<input type="checkbox"/> J33.0 - Polyp of nasal cavity	<input type="checkbox"/> J33.1 - Polypoid sinus degeneration
<input type="checkbox"/> J33.8 - Other polyp of sinus	<input type="checkbox"/> J33.9 - Nasal polyp, unspecified
<input type="checkbox"/> - Other:	

REQUESTED DOCUMENTATION: PREVIOUS ADMINISTRATION: HAS THIS PATIENT TAKEN THIS MEDICATION BEFORE?

1 Insurance information	IF NO:	IF YES:
2 Most recent History & Physical	PLEASE STATE	LAST INFUSION DATE:
3 Full medication list	REQUIRED WASHOUT	NEXT INFUSION DATE:
4 Tried and failed therapies	FROM PREVIOUS	IF ORDER CHANGE:
5 Pre-treatment serum IgE level as required for pretreatment dosing	THERAPY:	
		Continue current order until insurance approved

Provider Attestation for HCP administration:

<input type="checkbox"/> Provider attests that the patient or caregiver is not competent or is physically unable to administer the Xolair labeled self-administration.	<input type="checkbox"/> The location and circumstances for self-administration are not adequate for the potential treatment of anaphylaxis should that arise.
<input type="checkbox"/> Patient has experienced severe hypersensitivity reactions to Xolair or other agents, such as foods, drugs, biologics, within the past 6 months or requires administration and direct monitoring by a healthcare professional.	<input type="checkbox"/> Patient has a history of uncontrolled disease and ordering physician attests that in their clinical opinion, it is not advisable to try the self-administration formulation of requested drug
<input type="checkbox"/> Patient has not received at least 3 doses of Xolair under the guidance of a healthcare provider with no hypersensitivity reactions*	<input type="checkbox"/> Due to patient's weight, ordering provider attests that in their clinical opinion, it is not advisable to try the self-administered formulation of requested drug.

*Specific reactions:

MEDICATION ORDERS:

NOTE: Patient may be ineligible to receive Xolair® (omalizumab) if patient has signs/symptoms of parasitic infection, is currently being treated for a parasitic infection, or is having acute bronchospasm and/or asthma attack.

MEDICATION/FREQUENCY:

Xolair® (omalizumab) subcutaneously every 2 weeks: Xolair® (omalizumab) subcutaneously every 4 weeks:

DOSE:

75mg/dose
 150 mg/dose
 225mg/dose
 300mg/dose
 375mg/dose
 450mg/dose
 525mg/dose
 600mg/dose

Administer as subcutaneous injection to upper arm, thigh, or abdomen.

SPECIAL ORDERS:

POST WAIT: *Extended post treatment monitoring for any patient new to therapy*

Standard Palmetto Infusion Post wait per package insert: Monitor patient for two (2) hours after first injection, for (1) hour after second injection, for 30 minutes after third injection, then monitor for 15-minutes with all subsequent injections. Unless otherwise selected below.

Monitor patient for two (2) hours after first 3 injections, and for 30-minutes after all subsequent injections.
 Provider specific post wait: _____

Refills x 12 months unless noted otherwise here:

CARE ORDERS: ADVERSE REACTION & ANAPHYLAXIS ORDERS:

<input checked="" type="checkbox"/> Provide nursing care per Palmetto Infusion Nursing Procedures and post procedure observation if indicated	Administer acute infusion and anaphylaxis medications per Palmetto Infusion standing adverse reaction orders, which can be found at our website.
---	--

PRESCRIBER INFORMATION:

PROVIDER NAME:	PHONE:
ADDRESS:	FAX:
CITY, STATE, ZIP:	NPI:

PRESCRIBER SIGNATURE: (No stamp signatures) DATE

Dispense as written/Brand medically necessary	Substitution permitted	



Checklist for referrals to Palmetto Infusion: Fax referral to 1.866.872.8920

- Patient demographics - address, phone number, SS#, etc.**
- Insurance information - copy of the card(s) if possible**
- Plan of Treatment/Orders**
- Most recent physician office notes to include tried and failed therapies - all insurance companies that require a pre-authorization require the note. This includes Medicare/Medicaid HMOs.**
- Any lab results or other diagnostic procedures to support the diagnosis.**

Palmetto Infusion will complete insurance verification and submit all required clinical documentation to the patient's insurance company for eligibility.

Our office will notify you if any further information is required.

We will review financial responsibility with patient and refer them to any available co-pay assistance as required. Palmetto Infusion Call Center 800.809.1265. Thank you for your referral.

www.palmettoinfusion.com